| Literature DB >> 21441026 |
Tadashi Honda1, Albena T Dinkova-Kostova, Emilie David, Eric M Padegimas, Chitra Sundararajan, Melean Visnick, Ron Bumeister, W Christian Wigley.
Abstract
To explore more potent N-acylimidazole analogues of CDDO than CDDO-Im, which is one of the most potent compounds in several widely used bioassays related to protection against inflammation and carcinogenesis; we have synthesized and evaluated five new N-acyl(acetylenic)imidazole analogues. Among them, 4-ethynylimidazole 4 is nearly equivalent to CDDO-Im in potency in these bioassays. Remarkably, the solid form of 4 is more stable than that of CDDO-Im. These findings suggest that 4 is a very promising anti-inflammatory and cytoprotective agent and its further preclinical evaluation is warranted.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21441026 DOI: 10.1016/j.bmcl.2011.03.018
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823